BioIVT

Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.

Pharmaron is a contract research organization (CRO).

Services:
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services

www.pharmaron.com

CRO - Contract Research Organization
Library Synthesis
CADD
Bioorganic Chemistry
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
ChemInformatics
in vitro Biology
in vitro Screening
Structural Biology
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
Biomarkers
in vitro ADME
in vivo PK
PKPD
QA
Regulatory Affairs
Discovery Biologics
Process Chemistry
API Manufacturing
Material Science
Formulation Development
Drug Product Manufacturing
Toxicology
Safety Pharmacology
Genetic Toxicology
DART
Pathology
Immunotoxicity
Bioanalytical
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
QWBA
mARG
Clinical AME
Mass Balance
Metabolite Profiling
Microdosing Phase 0
Absolute Bioavailability
DDI
First-in-Human (FIH)
Thorough QT(TQT)
Ethnobridging

Our company is recognized for excellence in providing ISO 9001monoclonal and polyclonal antibodies, antigens, enzymes, and purified proteins to the research and medical diagnostic marketplace. Nearly all of our products are validated for usage in quantitative sandwich immunoassay and qualitative rapid testing.

We offer immunological reagents worldwide for diagnostics & research in the following disciplines:

Infectious Diseases (60)
Neuroscience (45)
Inflammation (43)
Veterinary (41)
Cardiac Markers (36)
Gangliosides & Globosides (33)
Tumor Markers (26)
Hormones (22)
Microbial & Plant Toxins (21)
Metabolic Syndrome (15)
Blood Coagulation and Anemia (12)
Biodefense (10)
Kidney Diseases (4)
Fertility and Pregnancy (2)


We are happy to inform you that Advanced ImmunoChemical is now offering a set of antibodies produced In vitro. In addition, some of our current antibodies are now available both as In vivo- and In vitro-produced products.

Monoclonal antibodies and mammalian antigens for detecting infectious diseases, cardiac biomarkers, and hormones.

Broad selection antibodies and inactivated viral antigens to detect Influenza A and B in clinical samples.
Monoclonal antibodies for the detection of biological threats and dangerous pathogens.

Biomarkers for cardiovascular disease prevention, risk assessment, and diagnostics.

Customers Include: Princeton University, Duke University School of Medicine, Columbia University Medical Center, CDC, National Institutes of Health, Naval Health Research Center, Los Alamos National Laboratory, US Army Medical Research Institute of Infectious Diseases, Sandia National Laboratories, Stanfored Medicine, NIST, NIMH, Harvard Medical School, Yale University School of Medicine, John Hopkins School of Medicine, Lawrence Livermore National Laboratory, and many more!

Advanced ImmunoChemical is a WBENC-certified woman-owned small business, since 1986.

Afraxis Inc. is a contract research organization (CRO) specializing in:

- CNS preclinical efficacy evaluations (in vivo & in vitro)
- Neurotoxicity evaluations
- Structure-Efficacy Relationship (SER) medicinal chemistry

The patented Afraxis ESP (Enhanced Spine Platform) technology produces a rapid, high-information read-out of synaptic networks from whole brain or other tissue preparations. The process incorporates (a) specialized labeling of individual neurons, (b) laser-scanning microscopy, (c) rapid and high-detail morphometry of individual synapses, and (d) novel powerful statistical methods tailored for big data analyses.

The Afraxis ESP platform was first developed within the original Afraxis, Inc. (now Afraxis Holdings), a company founded in 2007 to develop novel therapeutics for Fragile-X Syndrome (FXS) based on the work of Nobel laureate Susumu Tonegawa. The ESP technology was developed originally to solve an unmet need in Fragile-X drug discovery: the lack of a rapid tool to evaluate test compounds against dendritic spine abnormalities, the hallmark neuorbiological phenotype of FXS observed in both humans and rodent models. Considering the broad reach of dendritic spine abnormalitiies throughout CNS diseases, the tool was immediately applicable for other indications. The current Afraxis, Inc. was founded in April 2013 as a spin-out company by Christopher Rex and Carmine Stengone to develop the core ESP technology and drug discovery services.

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.

Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).

In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).

Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.

Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.

For more information, visit www.anaptysbio.com.

BioChroma Analytical Labs LLC is based out of the DFW metroplex in the heart of Texas. It was created to fill the technical gaps in new product development for innovators with new ideas that might not have all the necessary components to make it happen and to offer support for product quality through analytical testing and consulting. We provide an all-encompassing service to help our clients develop a product that is continually manufactured to the level of quality customers expect. Our goal is to provide continual scientific and technical support for entrepreneurs and established businesses based on quality at an affordable price. We are here to provide technical assistance to foster their idea from inception to the marketplace and beyond.
We have experience and expertise in research and development, formulations, scale-up, testing, quality and regulatory of a wide variety of consumer products in the areas of cosmetics, skin care, topical and oral OTCs, food, beverages, dietary supplements, household cleaners and the like.

Product Research and Development: Skin, Body, Hair Care Development, Dietary Supplement Development

Consulting: Packaging Advice, Manufacturing Advice, Plant Inspections, Ingredient Stability Advice, Container Closure Advice, Product Formulation Advice, Quality and Regulatory Advice

Chemistry Analysis: Nutritional Analysis, Mineral Analysis, Vitamin Analysis, Preservative Analysis, Active Ingredient Analysis, Allergen Analysis

Microbiological Analysis: General Microbiology Analysis, Pathogenic Bacteria Analysis, Spoilage Organism Analysis, Preservative Efficacy Analysis, Bacterial Challenge Studies, In vitro Time-Kill Studies, Antibiotic Studies, Water Suitability Testing

Laboratory Research and Development: Transdermal Studies, Antimicrobial Efficacy, Product Specific Studies Aimed at Demonstrating Efficacy or Quality